{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:43:22Z","timestamp":1793393002128,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009558","name":"University Natural Science Research Project of Anhui Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009558","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81502123"],"award-info":[{"award-number":["81502123"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973332"],"award-info":[{"award-number":["81973332"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People's Republic of China","doi-asserted-by":"publisher","award":["AYPYS2021-2"],"award-info":[{"award-number":["AYPYS2021-2"]}],"id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","award":["KFJJ-2020-12 KFJJ-2021-9"],"award-info":[{"award-number":["KFJJ-2020-12 KFJJ-2021-9"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["1308085QH130"],"award-info":[{"award-number":["1308085QH130"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejphar.2022.175091","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T11:31:04Z","timestamp":1655206264000},"page":"175091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":261,"special_numbering":"C","title":["Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome"],"prefix":"10.1016","volume":"928","author":[{"given":"Hao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-0693","authenticated-orcid":false,"given":"Yang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejphar.2022.175091_bib1","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.cgh.2015.07.029","article-title":"Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes","volume":"13","author":"Ahmed","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2022.175091_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2018.02.011","article-title":"Inflammasome biology, molecular pathology and therapeutic implications","volume":"187","author":"Awad","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.ejphar.2022.175091_bib3","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/gut.2009.197822","article-title":"Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome","volume":"59","author":"Bauer","year":"2010","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.ejphar.2022.175091_bib4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.0901363","article-title":"Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression","volume":"183","author":"Bauernfeind","year":"2009","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.ejphar.2022.175091_bib5","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.20172222","article-title":"Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity","volume":"215","author":"Boucher","year":"2018","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175091_bib6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1113\/expphysiol.2012.068338","article-title":"The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1beta","volume":"98","author":"Bracey","year":"2013","journal-title":"Exp. Physiol."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175091_bib7","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.chom.2010.11.007","article-title":"Differential requirement for Caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing","volume":"8","author":"Broz","year":"2010","journal-title":"Cell Host Microbe"},{"issue":"7628","key":"10.1016\/j.ejphar.2022.175091_bib8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature20412","article-title":"The road to restoring neural circuits for the treatment of Alzheimer's disease","volume":"539","author":"Canter","year":"2016","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ejphar.2022.175091_bib9","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/exd.12049","article-title":"Genetic support for the role of the NLRP3 inflammasome in psoriasis susceptibility","volume":"21","author":"Carlstrom","year":"2012","journal-title":"Exp. Dermatol."},{"issue":"9","key":"10.1016\/j.ejphar.2022.175091_bib10","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1084\/jem.20111453","article-title":"IL-1 beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells","volume":"209","author":"Coccia","year":"2012","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.ejphar.2022.175091_bib11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175091_bib12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejphar.2022.175091_bib13","unstructured":"Cooper, M.; Miller, D.; Macleod, A.; Van Wiltenburg, J.; Thom,S.; St Gallay, S.; Shannon, J.; Alanine, T. Novel Sulfonamide Carboxamide Compounds. WO 2019\/008025, Jan 10, 2019."},{"key":"10.1016\/j.ejphar.2022.175091_bib14","unstructured":"Cooper, M.; Miller, D.; Macleod, A.; Van Wiltenburg, J.; Thom,S.; St Gallay, S.; Shannon, J. Novel Sulfonamide Carboxamide Compounds. WO 2019\/034686, Feb 21, 2019."},{"issue":"9","key":"10.1016\/j.ejphar.2022.175091_bib15","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/liv.12537","article-title":"Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis","volume":"34","author":"Csak","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.ejphar.2022.175091_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12504","article-title":"Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models","volume":"7","author":"Daniels","year":"2016","journal-title":"Nat. Commun."},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2022.175091_bib17","article-title":"The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis","volume":"42","author":"Dayer","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejphar.2022.175091_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11929","article-title":"ASC filament formation serves as a signal amplification mechanism for inflammasomes","volume":"7","author":"Dick","year":"2016","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175091_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056100","article-title":"Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis","volume":"8","author":"Dixon","year":"2013","journal-title":"PLoS One"},{"issue":"7407","key":"10.1016\/j.ejphar.2022.175091_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nature11260","article-title":"Myocardial infarction accelerates atherosclerosis","volume":"487","author":"Dutta","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejphar.2022.175091_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/imr.12286","article-title":"Initiation and perpetuation of NLRP3 inflammasome activation and assembly","volume":"265","author":"Elliott","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejphar.2022.175091_bib22","series-title":"Non-Alcoholic Fatty Liver Disease: A Practical Guide, Non-alcoholic Fatty Liver Disease","author":"Farrell","year":"2013"},{"issue":"11","key":"10.1016\/j.ejphar.2022.175091_bib23","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/j.1462-5822.2006.00751.x","article-title":"Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages","volume":"8","author":"Fink","year":"2006","journal-title":"Cell Microbiol."},{"issue":"12","key":"10.1016\/j.ejphar.2022.175091_bib24","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1002\/eji.201343801","article-title":"TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis","volume":"43","author":"Flutter","year":"2013","journal-title":"Eur. J. Immunol."},{"issue":"Pt 19","key":"10.1016\/j.ejphar.2022.175091_bib25","first-page":"4423","article-title":"Cell cycle regulation by the NEK family of protein kinases","volume":"125","author":"Fry","year":"2012","journal-title":"J. Cell Sci."},{"issue":"4","key":"10.1016\/j.ejphar.2022.175091_bib26","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.immuni.2016.01.012","article-title":"Human monocytes engage an alternative inflammasome pathway","volume":"44","author":"Gaidt","year":"2016","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.ejphar.2022.175091_bib27","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1161\/01.ATV.16.8.1000","article-title":"Interleukin-1 beta in coronary arteries of patients with ischemic heart disease","volume":"16","author":"Galea","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejphar.2022.175091_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.04.022","article-title":"The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction","volume":"74","author":"Gao","year":"2019","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejphar.2022.175091_bib29","unstructured":"Glick, G.; Gosh, S.; Roush, W. R.; Shen, D.-M. Compounds and Compositions for Treating Conditions Associated with NLRP Activity. WO 2019\/023147, Jan 31, 2019."},{"issue":"8","key":"10.1016\/j.ejphar.2022.175091_bib30","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.4049\/jimmunol.1700245","article-title":"NLRP3 and potassium efflux drive rapid IL-1beta release from primary human monocytes during toxoplasma gondii infection","volume":"199","author":"Gov","year":"2017","journal-title":"J. Immunol."},{"issue":"40","key":"10.1016\/j.ejphar.2022.175091_bib31","doi-asserted-by":"crossref","first-page":"E9371","DOI":"10.1073\/pnas.1812744115","article-title":"Chloride regulates dynamic NLRP3-dependent ASC oligomerization and inflammasome priming","volume":"115","author":"Green","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4 Suppl. 26","key":"10.1016\/j.ejphar.2022.175091_bib32","first-page":"S45","article-title":"Fire and ICE: the role of pyrin domain-containing proteins in inflammation and apoptosis","volume":"20","author":"Gumucio","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175091_bib33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/cei.13167","article-title":"NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis","volume":"194","author":"Guo","year":"2018","journal-title":"Clin. Exp. Immunol."},{"issue":"8","key":"10.1016\/j.ejphar.2022.175091_bib34","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ni.1636","article-title":"The NALP3 inflammasome is involved in the innate immune response to amyloid-beta","volume":"9","author":"Halle","year":"2008","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.ejphar.2022.175091_bib35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ni.1636","article-title":"The NALP3 inflammasome is involved in the innate immune response to amyloid-beta","volume":"9","author":"Halle","year":"2008","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.ejphar.2022.175091_bib36","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","article-title":"Mechanism and regulation of NLRP3 inflammasome activation","volume":"41","author":"He","year":"2016","journal-title":"Trends Biochem. Sci."},{"issue":"7590","key":"10.1016\/j.ejphar.2022.175091_bib37","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nature16959","article-title":"NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux","volume":"530","author":"He","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2022.175091_bib38","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.96.12.4219","article-title":"Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study","volume":"96","author":"Hwang","year":"1997","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejphar.2022.175091_bib39","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.cyto.2014.12.014","article-title":"Cytokines in psoriasis","volume":"73","author":"Jaymie","year":"2015","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.ejphar.2022.175091_bib40","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.4049\/jimmunol.1003162","article-title":"IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression","volume":"186","author":"Johnston","year":"2011","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.ejphar.2022.175091_bib41","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.2174\/13894501113149990006","article-title":"Clinical strategies for the blockade of IL-18 in inflammatory bowel diseases","volume":"14","author":"Kanai","year":"2013","journal-title":"Curr. Drug Targets"},{"issue":"13","key":"10.1016\/j.ejphar.2022.175091_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ejphar.2022.175091_bib43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/med.1016","article-title":"Role of drug metabolism in drug discovery and development","volume":"21","author":"Kumar","year":"2001","journal-title":"Med. Res. Rev."},{"issue":"11","key":"10.1016\/j.ejphar.2022.175091_bib44","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1194\/jlr.M037861","article-title":"Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes\/macrophages","volume":"54","author":"L'Homme","year":"2013","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175091_bib45","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2337\/db12-0420","article-title":"Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes","volume":"62","author":"Lee","year":"2013","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.ejphar.2022.175091_bib46","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s00221-020-05916-6","article-title":"Protection of MCC950 against Alzheimer's disease via inhibiting neuronal pyroptosis in SAMP8 mice","volume":"238","author":"Li","year":"2020","journal-title":"Exp. Brain Res."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175091_bib47","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/gut.31.6.686","article-title":"Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease","volume":"31","author":"Ligumsky","year":"1990","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.ejphar.2022.175091_bib48","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0031-6997(24)01340-1","article-title":"Role of pharmacokinetics and metabolism in drug discovery and development","volume":"49","author":"Lin","year":"1997","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175091_bib49","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.103.057059","article-title":"The Interleukin-1\u03b2-Converting enzyme inhibitor pralnacasan reduces dextran sulfate Sodium-Induced murine colitis and t helper 1 T-Cell activation","volume":"308","author":"Loher","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175091_bib50","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2147\/CLEP.S33961","article-title":"A clinical review of recent findings in the epidemiology of inflammatory bowel disease","volume":"5","author":"Long","year":"2013","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.ejphar.2022.175091_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2019.106657","article-title":"Murine models of psoriasis and its applications in drug development","volume":"101","author":"Luo","year":"2020","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"9","key":"10.1016\/j.ejphar.2022.175091_bib52","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrd.2018.149","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175091_bib53","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol. Cell"},{"issue":"7081","key":"10.1016\/j.ejphar.2022.175091_bib54","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"issue":"48","key":"10.1016\/j.ejphar.2022.175091_bib55","doi-asserted-by":"crossref","first-page":"33835","DOI":"10.1074\/jbc.274.48.33835","article-title":"ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells","volume":"274","author":"Masumoto","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175091_bib56","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/gut.42.2.214","article-title":"Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease","volume":"42","author":"Mcalindon","year":"1998","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.ejphar.2022.175091_bib57","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"Mcinnes","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"23","key":"10.1016\/j.ejphar.2022.175091_bib58","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"Mcinnes","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175091_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2011.04440.x","article-title":"The NLRP3 inflammasome in health and disease: the good, the bad and the ugly","volume":"166","author":"Menu","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejphar.2022.175091_bib60","unstructured":"Miller, D.; Macleod, A.; Van Wiltenburg, J.; Thom, S.;Shannon, J. Novel Sulfonamide Carboxamide Compounds. WO 2019\/034697, Feb 21, 2019."},{"issue":"5","key":"10.1016\/j.ejphar.2022.175091_bib61","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175091_bib62","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.immuni.2013.05.016","article-title":"K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter","volume":"38","author":"Munoz-Planillo","year":"2013","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.ejphar.2022.175091_bib63","article-title":"NLRP3 inflammasome expression and activation in human atherosclerosis","volume":"5","author":"Paramel","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175091_bib64","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1517\/17425255.2012.652084","article-title":"Preclinical in vivo ADME studies in drug development: a critical review","volume":"8","author":"Pellegatti","year":"2012","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175091_bib65","doi-asserted-by":"crossref","first-page":"8618","DOI":"10.1038\/s41598-018-26775-w","article-title":"MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice","volume":"8","author":"Perera","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175091_bib66","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-3565(24)29317-4","article-title":"Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors","volume":"299","author":"Perregaux","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"9","key":"10.1016\/j.ejphar.2022.175091_bib67","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/sj.cdd.4402195","article-title":"Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration","volume":"14","author":"Petrilli","year":"2007","journal-title":"Cell Death Differ."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175091_bib68","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.4049\/jimmunol.1600035","article-title":"Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation","volume":"197","author":"Primiano","year":"2016","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175091_bib69","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.4049\/jimmunol.1600035","article-title":"Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation","volume":"197","author":"Primiano","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2022.175091_bib70","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.phrs.2016.11.004","article-title":"Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy","volume":"114","author":"Qiu","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.ejphar.2022.175091_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112379","article-title":"Regulation and sensing of inflammasomes and their impact on intestinal health","volume":"18","author":"Ranson","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"42","key":"10.1016\/j.ejphar.2022.175091_bib72","doi-asserted-by":"crossref","first-page":"39320","DOI":"10.1074\/jbc.M104730200","article-title":"Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis","volume":"276","author":"Richards","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175091_bib73","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.it.2013.02.006","article-title":"Caspase recruitment domain-containing protein 9 signaling in innate immunity and inflammation","volume":"34","author":"Roth","year":"2013","journal-title":"Trends Immunol."},{"issue":"10","key":"10.1016\/j.ejphar.2022.175091_bib74","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1002\/eji.201545772","article-title":"Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux","volume":"45","author":"Ruhl","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"12","key":"10.1016\/j.ejphar.2022.175091_bib75","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1021\/acsmedchemlett.6b00198","article-title":"Identification, synthesis, and biological evaluation of the major human metabolite of NLRP3 inflammasome inhibitor MCC950","volume":"7","author":"Salla","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175091_bib76","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/bpa.12785","article-title":"Distinct disease-sensitive GABAergic neurons in the perirhinal cortex of Alzheimer's mice and patients","volume":"30","author":"Sanchez-Mejias","year":"2020","journal-title":"Brain Pathol."},{"key":"10.1016\/j.ejphar.2022.175091_bib77","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.imlet.2017.10.010","article-title":"Inflammasomes and type 2 diabetes: an updated systematic review","volume":"192","author":"Sepehri","year":"2017","journal-title":"Immunol. Lett."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175091_bib78","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1083\/jcb.201602089","article-title":"The cell biology of inflammasomes: mechanisms of inflammasome activation and regulation","volume":"213","author":"Sharma","year":"2016","journal-title":"J. Cell Biol."},{"issue":"7","key":"10.1016\/j.ejphar.2022.175091_bib79","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.autrev.2018.01.020","article-title":"NLRP3: a promising therapeutic target for autoimmune diseases","volume":"17","author":"Shen","year":"2018","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.ejphar.2022.175091_bib80","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ni.3333","article-title":"NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component","volume":"17","author":"Shi","year":"2016","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.ejphar.2022.175091_bib81","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","article-title":"Pyroptosis: gasdermin-Mediated programmed necrotic cell death","volume":"42","author":"Shi","year":"2017","journal-title":"Trends Biochem. Sci."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175091_bib82","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/gut.50.6.812","article-title":"Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage","volume":"50","author":"Sivakumar","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2022.175091_bib83","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.abb.2019.01.031","article-title":"The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout","volume":"670","author":"Szekanecz","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175091_bib84","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41467-017-00227-x","article-title":"CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation","volume":"8","author":"Tang","year":"2017","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175091_bib85","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1053\/j.gastro.2010.01.058","article-title":"Inflammation and colon cancer","volume":"138","author":"Terzic","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2022.175091_bib86","unstructured":"Trial Trove.TrialTroveID-362962, A Phase 1, Double-BlindPlacebo-Controlled Single Multiple Ascending Dose Study of Safety,Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effects orIFM-2427 in Healthy Subjects.https:\/\/citeline.informa.com\/trials\/details\/362962?qId=6c9b6f61-bad0-48e6-9c80-d93c3eaa3a2e(accessed Jan 8, 2022)."},{"key":"10.1016\/j.ejphar.2022.175091_bib87","unstructured":"Trial Trove.TrialTroveID-368867, A Phase II Proof of Concept Study of Somalix to Address Clinical Unmet Needs in Inflammatory Conditions Such as Arthritis and Cardiovascular Disease. https:\/\/citeline.informa.com\/trials\/details\/357081?qId=bdc4f6b3-6b69-459c-b2ee-8a4dbf19fe13(accessed Jan 8, 2022)."},{"key":"10.1016\/j.ejphar.2022.175091_bib88","unstructured":"Trial Trove.TrialTroveID-360928, The Multiple Proof of Concept Studies of Phase II Inzomelid in Patients with Parkinson's Disease. https:\/\/citeline.informa.com\/trials\/details\/360928?qId=79b241fb-63ac-4d15-a542-d6b6849d357c(accessed Jan 8, 2022)."},{"key":"10.1016\/j.ejphar.2022.175091_bib89","unstructured":"Trial Trove.TrialTroveID-357081, A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of IZD334 in Healthy Adult Participants as Well as an Open-Label Cohort to Confirm the Safety, Pharmacokinetics, and Pharmacodynamics in Adult Patients With Cryopyrin-Associated Periodic Syndromes. https:\/\/citeline.informa.com\/trials\/details\/357081?qId=bdc4f6b3-6b69-459c-b2ee-8a4dbf19fe13(accessed Jan 8, 2022)."},{"key":"10.1016\/j.ejphar.2022.175091_bib90","unstructured":"Trial Trove.TrialTroveID-353058, A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Inzomelid in Healthy Adult Participants as Well as an Open Label Cohort to Confirm the Safety, Pharmacokinetics, and Pharmacodynamics of Inzomelid in Adult Patients with Cryopyrin-Associated Periodic Syndromes. https:\/\/citeline.informa.com\/trials\/details\/353058?qId=9029e7c5-e0d5-449a-851a-d762b6047856(accessed Jan 8, 2022)."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175091_bib91","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1053\/j.ajkd.2017.10.026","article-title":"Update on diabetic nephropathy: core curriculum 2018","volume":"71","author":"Umanath","year":"2018","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"10.1016\/j.ejphar.2022.175091_bib92","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.it.2011.01.003","article-title":"Inflammasome activation and IL-1beta and IL-18 processing during infection","volume":"32","author":"van de Veerdonk","year":"2011","journal-title":"Trends Immunol."},{"issue":"8","key":"10.1016\/j.ejphar.2022.175091_bib93","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1161\/ATVBAHA.117.309575","article-title":"NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E-Deficient Mice-Brief report","volume":"37","author":"van der Heijden","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175091_bib94","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.2279","article-title":"The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance","volume":"17","author":"Vandanmagsar","year":"2011","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.ejphar.2022.175091_bib95","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.4049\/jimmunol.175.11.7623","article-title":"Inhibitory effects of chloride on the activation of caspase-1, IL-1beta secretion, and cytolysis by the P2X7 receptor","volume":"175","author":"Verhoef","year":"2005","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175091_bib96","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneph.2015.175","article-title":"Innate immunity in diabetes and diabetic nephropathy","volume":"12","author":"Wada","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"issue":"12","key":"10.1016\/j.ejphar.2022.175091_bib97","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrrheum.2010.157","article-title":"Psoriasis: what we have learned from mouse models","volume":"6","author":"Wagner","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejphar.2022.175091_bib98","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.2147\/DMSO.S222053","article-title":"NLRP3 inflammasome promotes diabetes-induced endothelial inflammation and atherosclerosis","volume":"12","author":"Wan","year":"2019","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"33","key":"10.1016\/j.ejphar.2022.175091_bib99","doi-asserted-by":"crossref","first-page":"29874","DOI":"10.1074\/jbc.M203915200","article-title":"PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing","volume":"277","author":"Wang","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.ejphar.2022.175091_bib100","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s13238-013-3905-0","article-title":"The NLRP3 inflammasome activation in human or mouse cells, sensitivity causes puzzle","volume":"4","author":"Wang","year":"2013","journal-title":"Protein Cell"},{"issue":"12","key":"10.1016\/j.ejphar.2022.175091_bib101","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1038\/jid.2013.237","article-title":"IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis","volume":"133","author":"Wang","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2022.175091_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115954","article-title":"MCC950, a NLRP3 inhibitor, ameliorates lipopolysaccharide-induced lung inflammation in mice","volume":"30","author":"Wang","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejphar.2022.175091_bib103","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/ni.2022","article-title":"Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling","volume":"12","author":"Wen","year":"2011","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.ejphar.2022.175091_bib104","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.cell.2016.05.076","article-title":"Hexokinase is an innate immune receptor for the detection of bacterial peptidoglycan","volume":"166","author":"Wolf","year":"2016","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ejphar.2022.175091_bib105","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/hep.26592","article-title":"NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice","volume":"59","author":"Wree","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ejphar.2022.175091_bib106","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.bbrc.2018.08.089","article-title":"The selective Nlrp3 inflammasome inhibitor Mcc950 attenuates lung ischemia-reperfusion injury","volume":"503","author":"Xu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7202","key":"10.1016\/j.ejphar.2022.175091_bib107","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature07021","article-title":"IL-21 and TGF-beta are required for differentiation of human T(H)17 cells","volume":"454","author":"Yang","year":"2008","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejphar.2022.175091_bib108","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.clim.2015.02.001","article-title":"Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation","volume":"157","author":"Zhang","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ejphar.2022.175091_bib109","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2147\/DMSO.S199802","article-title":"A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation","volume":"12","author":"Zhang","year":"2019","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"3","key":"10.1016\/j.ejphar.2022.175091_bib110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/15476286.2019.1700058","article-title":"NLRP3 inflammasome activation by Foot-and-mouth disease virus infection mainly induced by viral RNA and non-structural protein 2B","volume":"17","author":"Zhi","year":"2020","journal-title":"RNA Biol."},{"key":"10.1016\/j.ejphar.2022.175091_bib111","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5702103","article-title":"NLRP3: a novel mediator in cardiovascular disease","volume":"2018","author":"Zhou","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.ejphar.2022.175091_bib112","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5702103","article-title":"NLRP3: a novel mediator in cardiovascular disease","volume":"2018","author":"Zhou","year":"2018","journal-title":"J. Immunol. Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922003521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922003521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:18:35Z","timestamp":1762143515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922003521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":112,"alternative-id":["S0014299922003521"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175091","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175091"}}